Zedira licenses ZED-101 for celiac disease therapy to Dr. Falk Pharma in Europe
Zedira GmbH today announced that it has licensed exclusive rights to develop and market ZED-101 in Europe to Dr. Falk Pharma GmbH, Germany. ZED-101 is a new chemical entity blocking specifically tissue transglutaminase. Tissue transglutaminase is the key player in pathogenesis of celiac disease.
Under the terms of the agreement, Dr. Falk Pharma GmbH takes over preclinical and clinical development as well as marketing of the drug.
Zedira receives an upfront payment and may receive further milestone payments as well as royalties.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.